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Abstract
Background: Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM).
Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomodulatory
drugs, myeloma-targeted antibodies, and histone deacetylase inhibitors, MM is still considered an incurable disease.
Methods: We investigated whether the clinical exportin 1 (XPO1) inhibitor selinexor (KPT-330), when combined with
pegylated liposomal doxorubicin (PLD) or doxorubicin hydrochloride, could overcome acquired drug resistance in
multidrug-resistant human MM xenograft tumors, four different multidrug-resistant MM cell lines, or ex vivo
MM biopsies from relapsed/refractory patients. Mechanistic studies were performed to assess co-localization of
topoisomerase II alpha (TOP2A), DNA damage, and siRNA knockdown of drug targets.
Results: Selinexor was found to restore sensitivity of multidrug-resistant 8226B25, 8226Dox6, 8226Dox40, and
U266PSR human MM cells to doxorubicin to levels found in parental myeloma cell lines. NOD/SCID-γ mice
challenged with drug-resistant or parental U266 human MM and treated with selinexor/PLD had significantly
decreased tumor growth and increased survival with minimal toxicity. Selinexor/doxorubicin treatment selectively
induced apoptosis in CD138/light-chain-positive MM cells without affecting non-myeloma cells in ex vivo-treated
bone marrow aspirates from newly diagnosed or relapsed/refractory MM patients. Selinexor inhibited XPO1-TOP2A
protein complexes (proximity ligation assay), preventing nuclear export of TOP2A in both parental and multidrug-
resistant MM cell lines. Selinexor/doxorubicin treatment significantly increased DNA damage (comet assay/γ-H2AX) in
both parental and drug-resistant MM cells. TOP2A knockdown reversed both the anti-tumor effect and significantly
reduced DNA damage induced by selinexor/doxorubicin treatment.
Conclusions: The combination of an XPO1 inhibitor and liposomal doxorubicin was highly effective against acquired
drug resistance in in vitro MM models, in in vivo xenograft studies, and in ex vivo samples obtained from patients with
relapsed/refractory myeloma. This drug combination synergistically induced TOP2A-mediated DNA damage and
subsequent apoptosis. In addition, based on our preclinical data, we have initiated a phase I/II study with the XPO1
inhibitor selinexor and PLD (ClinicalTrials.gov NCT02186834). Initial results from both preclinical and clinical trials have
shown significant promise for this drug combination for the treatment of MM.
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Background
In cancer cells, the location of a tumor-suppressive or
oncogenic protein within the cell is as important as its
expression. We have shown that cancer cells utilize the
process of nuclear-cytoplasmic transport through the
nuclear pore complex to effectively evade anti-cancer
mechanisms [1–5]. In our previous studies, we have
shown that knockdown of exportin 1 (XPO1) protein by
siRNA or inhibition with an XPO1 inhibitor will sensitize
drug-resistant myeloma cells to the topoisomerase II
(TOP2) inhibitor doxorubicin [3, 5]. We have also shown
that XPO1 inhibitors are able to prevent nuclear export
and promote nuclear accumulation of the tumor suppres-
sor protein p53, and prevent the export of the drug target
TOP2A [3, 5]. In addition, XPO1 inhibitors were found to
reverse de novo drug-resistance of multiple myeloma
(MM) cells in high-density cell culture models and drug
resistance conferred to MM cell lines when co-cultured
with bone marrow stromal cells [5].
Recent publications have indicated that XPO1 inhibi-
tors, particularly the orally available clinical compound
selinexor (KPT-330), may be effective against various
malignancies, including breast cancer [6, 7], glioblastoma
[8], hepatocellular carcinoma [9], kidney cancer [10, 11],
leukemia [12–16], lung cancer [17], mantle cell lymphoma
[18, 19], melanoma [20, 21], mesothelioma [22], non-
Hodgkin lymphoma [23], ovarian cancer [7], pancreatic can-
cer [24, 25], prostate cancer [25, 26], and MM [5, 13, 27].
Recent studies in MM have shown that XPO1 protein
levels are increased in plasma cells from newly diag-
nosed MM patients when compared with normal plasma
cells [13, 27] or with plasma cells from those with
monoclonal gammopathy of undetermined significance
and smoldering MM [27]. In addition, high levels of
XPO1 may be associated with decreases in event-free
and overall survival in MM [13]. When treated with XPO1
inhibitors, 21 different human MM cell lines were found
to have decreased cell viability [3, 5, 13, 27]. XPO1 inhibi-
tors in MM have been shown to dysregulate the following
cancer-related proteins or mRNAs: c-myc, CDC25A,
BRD4, p53, Mcl-1, BCl-xL, NF-kB, p21, p27, IkB,
FOXO3A, FOXO1A, PP2A, PUMA, BAX, CHOP, C1-
0orf10, MIC1, IL-6, VEGF, MIP1ß, and IL-10 [5, 13, 27].
What has not been addressed in previous studies is
whether XPO1 inhibitors are effective in overcoming ac-
quired drug-resistant MM phenotypes, which develop in
patients during treatment with standard of care therapies.
In patients with MM, acquired drug resistance is a major
obstacle, as the disease is considered incurable despite sig-
nificant advances afforded by immunomodulatory drugs
(thalidomide, lenalidomide, pomalidomide), proteasome
inhibitors (bortezomib, carfilzomib, ixazomib), antibodies
targeting SLAMF7 protein (elotuzumab) and CD-38 (dar-
atumumab), histone deacetylase inhibitors (panobinostat),
and high-dose chemotherapy with autologous stem cell
rescue.
The recent resurgence of doxorubicin as a treatment
for multiple myeloma has been observed in the clinic
due to its reformulation in poly(ethylene glycol)-coated
liposomes. This formulation increases circulation time
and has a unique toxicity profile, including mild myelo-
suppression, minimal alopecia, and no cardiac toxicity.
In addition, liposomal doxorubicin accumulates preferen-
tially in tissues with increased microvascular permeability
seen in cancers [28–30]. In the present study, we show
that XPO1 inhibition sensitized drug-resistant MM cells
to liposomal doxorubicin in in vitro and in vivo models
and ex vivo in relapsed/refractory patient MM cells, thus
demonstrating that this combination may provide the
means for overcoming acquired drug resistance in MM.
Methods
Cell lines
Human MM cell lines RPMI 8226, U266, and NCI-H929
were obtained from the American Type Culture Collec-
tion (ATCC; Manassas, VA). MM cell lines 8226B25 and
U266PSR were developed incrementally [31, 32]. The
U266PSR cell line expresses a modest increase in Mcl-1
[33] and markedly lower expression of the apoptosis-
promoting factor Bim [31, 32], resulting in enhanced cell
survival by inhibiting apoptosis. Doxorubicin-resistant
8226Dox6 and 8226Dox40 cell lines were produced by
the incremental addition of doxorubicin [34]; these cell
lines were found to overexpress the MDR1 gene, which
prevented intracellular accumulation of doxorubicin,
resulting in resistance [35, 36]. All cell lines were authenti-
cated by the Moffitt Cancer Center Molecular Genomics
Core Facility according to ATCC guidelines [37].
Drug-resistant cell lines treated with XPO1 inhibitors and
doxorubicin
Parental 8226 and U226 and drug-resistant 8226B25,
8226Dox6, 8226Dox40, and U266PSR human MM cells
were grown at low-density (log growth phase) conditions
(3–4 × 105 cells/mL) and cultured for 20 h with either
300 nM selinexor (Karyopharm Therapeutics) or 10 nM
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KOS-2464 (Bristol-Myers Squibb) with and without
2 μM doxorubicin (Sigma Chemical). Optimal drug con-
centrations were determined by titration experiments.
Cells were fixed in Cytofix/Cytoperm buffer (Becton-
Dickinson) and permeabilized in Perm/Wash buffer
(Becton-Dickinson), and apoptosis was measured by flow
cytometry using anti-activated caspase 3/Alexa Fluor
488 (Cell Signaling Technology) staining.
Bone marrow aspirate processing and apoptosis assay of
patient myeloma cells
Bone marrow aspirates were collected from newly diag-
nosed (n = 19) and relapsed (n = 12)/refractory (n = 10)
patients. Isolated bone marrow mononuclear cells were
incubated at 4–8 × 106/mL in 200 μL RPMI (Fisher) con-
taining 10 % FBS in 96-well plates, treated with either
selinexor (300 nM) or KOS-2464 (300 nM) with and
without 2 μM doxorubicin, and incubated for 20 h in a
5 % CO2 humidified incubator. The cells were then fixed
and assayed for apoptosis according to methods outlined
in Turner et al. [5].
NOD/SCID-γ mouse studies with selinexor ± PLD
Drug-resistant U266PSR human myeloma cells (106) or
parental U266 cells (5 × 106) were injected subcutaneously
into flanks of female NOD/SCID-γ mice, and tumors were
allowed to grow for 14 days before the start of treatment
[31]. Mice were treated with PLD (0.5 mg/kg) once weekly
by intraperitoneal injection, by oral gavage with selinexor
(10 mg/kg) twice weekly, or with the combination where
selinexor treatment was followed 1–2 h later by PLD in-
jection. Five mice were used per experimental group. Tu-
mors were measured by calipers, and tumor volumes
(mm3) were calculated by the formula (length × width2)/2.
Animals were killed upon achieving a tumor volume
>2000 mm3 or if the mouse lost >15 % of its body weight;
this was used to define survival. Drug toxicity was assayed
by mouse weights with a decrease of ≥10 % considered an
indication of toxicity by the drug regimen.
Proximity ligation assay
Log-phase H929, 8226, 8226B25, 8226Dox6, U226, and
U226PSR MM cells were placed at plateau conditions
(4 × 106 cells/mL) and treated with 300 nM selinexor for
4 h. Cells were washed with PBS, and cytospins were
made at 1 × 105 cells/slide and fixed with 4 % parafor-
maldehyde/PBS and permeabilized with 0.5 % Triton X-
100. Slides were blocked in 2 % BSA/PBS and incubated
with primary antibodies to TOP2A (Kis1; Millipore) and
XPO1 (H-300; Santa Cruz). Proximity ligation assay was
performed according to the manufacturer’s protocol
(Olink Bioscience, Uppsala, Sweden) [38]. A red fluores-
cent signal was generated only when XPO1 and TOP2A
were in close proximity (<40 nm). 4′,6-Diamidino-2-
phenylindole (DAPI) was used to stain the nuclei. Sam-
ples were observed with a Leica TCS SP5 AOBS laser
scanning confocal microscope. The total number of foci
per nucleus and cell were analyzed for number and area.
This experiment was repeated three times. Western
blots were made of the selinexor-treated cells at 4 h for
XPO1 and TOP2A protein expression levels.
Neutral comet assay
Drug-resistant 8226B25, 8226Dox6, and U266PSR and
parental 8226 and U226 cells grown under log-phase
conditions were placed at high-density conditions (2–
4 × 106 cells/mL), and selinexor (100 nM) was added to
media for 20 h followed by the addition of 5 μM doxo-
rubicin for 1 h. Neutral comet assay to determine DNA
damage was performed according to the manufacturer’s
protocol (Trevigen, Gaithersburg, MD) [39, 40]. Protein-
ase K was added to digest any protein-associated DNA
damage caused by topoisomerase-mediated formation of
cleavable complexes, indicating that DNA damage was
due to double-strand breaks produced from TOP2 [41].
Electrophoresis was performed at room temperature in
TBE buffer at a constant 0.85 V/cm for 15 min. Slides
were rinsed very briefly with ddH2O and then fixed in
70 % ethanol for 5 min. Slides were air-dried and then
stored at room temperature in a slide box containing
desiccant until comets were stained and viewed by mi-
croscopy. Comets were stained with SYBR green
(Molecular Probes) diluted at 1:10,000 in TBE. Images
were taken with ×40 objective lens using a fluorescein
filter. The Loats Associates Incorporated Comet Analysis
System was used to calculate tail moment [42], which is
the product of distance and normalized intensity inte-
grated over the tail length. This is a damage measure-
ment combining the amount of DNA in the tail with the
distance of migration (severity of damage). A minimum of
50 comets were analyzed for each dose, and each experi-
ment was repeated three times.
Gamma-H2AX and TOP2A knockdown
Cells were treated with single-agent doxorubicin (2 μM),
selinexor (300 nM), and their combination for 20 h and
then assayed for phospho-H2AX (Ser139) expression
(JBW301, FITC conjugate, Millipore) by flow cytometry
(n = 4). To determine if apoptosis and DNA strand breaks
are dependent on the presence of TOP2A, H929 MM cells
were transfected by electroporation with a TOP2A-specific
siRNA (Silencer Select Validated cat. #4390824, Ambion).
Electroporation of MM cells was accomplished by a
method outlined in Turner et al. [3]. A control group of
cells was transfected with a non-coding siRNA. Transfected
(TOP2A knockdown and control siRNA) H929 MM cells
were then incubated with selinexor (300 nM) +/−
doxorubicin (2 μM) for 20 h and assayed by flow cytometry
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for DNA double-strand breaks using phospho-H2AX
(Ser139) expression (JBW301) and apoptosis by activated-
caspase 3 (ASP175, AF488, Cell Signaling).
Results
XPO1 inhibition sensitizes drug-resistant MM cell lines to
doxorubicin
Apoptosis results (flow cytometry using activated caspase
3) in human drug-resistant and parental MM cells after
20-h concurrent treatment with selinexor (300 nM) or
KOS-2464 (10 nM) ± doxorubicin (2 μM) are shown in
Fig. 1. Both U266 and 8226 parental cell lines were highly
sensitive to single-drug treatment with doxorubicin. Drug-
resistant 8226B25 (Fig. 1a) and U266PSR MM cell lines
(Fig. 1b) and doxorubicin-resistant 8226Dox6 (Fig. 1c) and
8266Dox40 MM cell lines (Fig. 1d) were resistant to
single-agent doxorubicin (5.9-, 11.6-, 16.7-, and 10.7-fold,
respectively) compared with parental cells. The XPO1
Fig. 1 XPO1 inhibition sensitizes drug-resistant human MM cell lines to doxorubicin (DOX). Human 8226B25 (a), U266PSR (b), 8226Dox6 (c), and
8226Dox40 (d) drug-resistant and parental MM cell lines were treated concurrently for 20 h with selinexor (300 nM) or KOS-2464 (10 nM) +/−
doxorubicin (2 μM) and assayed for apoptosis by flow cytometry (activated caspase 3) (n = 3). XPO1 inhibitors sensitized drug-resistant cells to
DOX compared with single-agent treatment
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inhibitor selinexor sensitized drug-resistant human MM
8226B25 (P = 0.0060), U266PSR (P = 0.0023), 8226Dox6
(P = 0.029), and 8226Dox40 (P = 0.0077) cell lines to
doxorubicin compared with single-agent treatment with
doxorubicin alone. In addition, KOS-2464 also sensi-
tized drug-resistant human MM 8226B25 (P = 0.0023),
U266PSR (P = 0.0034), 8226Dox6 (P = 0.0.029), and
8226Dox40 (P = 0.0077) cell lines to doxorubicin com-
pared with single-agent treatment with doxorubicin
alone (Fig. 1a–d).
Ex vivo treatment of newly diagnosed, relapsed/refractory
patient MM cells with KOS-2464 and selinexor sensitizes
cells to doxorubicin
CD138+/light chain+ MM cells were isolated from bone
marrow aspirates from newly diagnosed (n = 19) and re-
lapsed (n = 12) or refractory (n = 10) patients. The re-
lapsed/refractory patients had received therapies that
included an average of 4.7 regimens of chemotherapy,
including two or more of the following drugs or drug
combinations: busulfan, carfilzomib, cytoxan, dexametha-
sone, elutozumab, pegylated liposomal doxorubicin
(PLD or Doxil), panobinostat, pomalidomide, prednisone,
revlimid (lenalidomide), velcade (bortezomib), and mel-
phalan with autologous stem cell transplantation.
Both newly diagnosed and relapsed/refractory MM pa-
tient cells were sensitized by selinexor (P = 8.0 × 10−11 and
P = 1.37 × 10−8, respectively) and KOS-2464 (P = 9.9 × 10−11
and P = 7.3 × 10−9, respectively) to doxorubicin (Fig. 2a, c)
as shown by activated caspase 3 staining and detection by
flow cytometry. In contrast, CD138/light-chain double-
negative non-myeloma cells from the same patient bone
marrow aspirates were not sensitized to apoptosis by XPO1
inhibitors (Fig. 2b, d).
In vivo NOD/SCID-γ mouse studies with selinexor and PLD
In mouse studies, drug-resistant U266PSR human MM
cells and parental U266 cells controls were used. U266PSR
A B
C D
Fig. 2 Selinexor and KOS-2464 sensitize newly diagnosed and relapsed patient MM cells to doxorubicin. Bone marrow mononuclear cells were
isolated and treated with selinexor or KOS-2464 +/− doxorubicin and fluorescently labeled with antibodies against activated caspase 3, CD138,
and light chain (kappa or lambda). Newly diagnosed (n = 19) and relapsed (n = 22) CD-138/light-chain double-positive MM patient samples were
all sensitized by selinexor and KOS-2464 to doxorubicin (P ≤ 1.37 × 10−8) versus single-agent treatment as shown by increased apoptosis (a, c).
Non-myeloma CD138/light-chain double-negative patient cells were not sensitized to apoptosis by XPO1 inhibitors (b, d)
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cells have been shown to be approximately seven- to eight-
fold more resistant to doxorubicin than U226 parental cells
(Fig. 1b) [31–33]. As shown in Fig. 3b, PLD combined with
selinexor reduced parental U266 tumor growth versus
single-agent PLD (P = 0.0003) or selinexor (P = 0.0079).
PLD combined with selinexor also reduced drug-resistant
U266PSR tumor growth (Fig. 3a) versus single-agent
PLD (P = 0.001) or selinexor (P = 0.009). Selinexor/PLD
significantly improved survival in U266-challenged mice
when compared with single-agent selinexor (P = 0.0002)
or PLD (P = 0.0024) (Fig. 3d) and in U266PSR when
compared with selinexor (P = 0.0095) or PLD (P = 0.0018)
(Fig. 3c). At the end of the study (4 months), 40 % of the
U266PSR-challenged mice and 60 % of the U266 par-
ental MM-challenged mice had survived; all untreated
control, single-agent PLD-treated, and selinexor-
treated mice were euthanatized due to tumor size
(>2000 mm3) before the end of the study. Toxicity,
assessed by weight loss greater than 10 %, was less
than 2 % in all treatment groups.
Selinexor inhibits XPO1-TOP2A binding
To determine whether selinexor specifically inhibits
XPO1-TOP2A binding, proximity ligation assays were
performed on parental 8226, H929, and U266 MM cell
lines and drug-resistant 8226B25, 8226Dox6, and
U226PSR cell lines (Fig. 4). Selinexor blocked proxim-
ity co-localization of XPO1 and TOP2A as shown by
the number of XPO1-TOP2A foci (Fig. 4a). Selinexor
significantly decreased the number of foci in the nu-
cleus and whole cells (Fig. 4b) in H929 (P ≤ 0.004),
U266 (P ≤ 0.001), U266PSR (P ≤ 0.033), 8226 (P ≤ 0.0004),
8226Dox6 (P ≤ 0.005), and 8226B25 (P ≤ 0.046) cells.
XPO1 and TOP2A protein levels were unaffected by seli-
nexor treatment for up to 4–6 h (Fig. 4a, inset). Selinexor
covalent modification of the XPO1 binding site precluded
Fig. 3 In vivo studies. PLD/selinexor treatment reduced drug-resistant U266PSR (a) and parental U266 (b) tumor growth compared with single-
agent treatment with PLD (P = 0.001) or selinexor (P = 0.009) in drug-resistant U266PSR (a) and PLD (P = 0.0003) or selinexor (P = 0.0079) in parental
U266 (b). c, d: Selinexor/PLD significantly improved survival in U266PSR-challenged mice compared with single-agent selinexor (P = 0.0095) or
PLD (P = 0.0018) (c) and in U266 compared with selinexor (P = 0.0002) or PLD (P = 0.0024) (d)
Turner et al. Journal of Hematology & Oncology  (2016) 9:73 Page 6 of 11
XPO1 binding the nuclear export signal of TOP2A, thus
preventing the nuclear export of TOP2A and increasing
the amount of nuclear enzyme.
XPO1 inhibitors increased DNA damage when used with
doxorubicin
Human 8226 MM cells (2 × 106/mL) were treated with
selinexor (100 nM) for 20 h followed by doxorubicin
(5 μM) for an additional 1 h, and DNA fragmentation
was measured by the neutral comet assay (Fig. 5). Seli-
nexor/doxorubicin treatment increased DNA damage over
single-agent doxorubicin or selinexor in U266 (P= 3.2 × 10−6/
P= 2.5 × 10−5), PSR (P= 9.9 ×1 0−9/P = 6.7 × 10−12), 8226
(P = 2.4 × 10−10/P = 3.8 × 10−11), 8226Dox6 (P = 3.1 × 10−9/
P = 4.6 × 10−8), and B25 (P = 3.4 × 10−17/P = 4.7 × 10−21)
MM cell lines (n = 50 comets each per cell line and treat-
ment condition for three experiments each) (Fig. 5).
DNA damage and apoptosis induced by selinexor/
doxorubicin is TOP2A dependent
DNA damage was measured by phospho-H2AX expres-
sion in selinexor- and doxorubicin-treated cells. 8226,
8226B25, 8226Dox6, U266, and U266PSR human MM
cells were treated concurrently for 20 h and stained for
phospho-H2AX expression by flow cytometry (Fig. 6).
DNA damage was synergistically induced by the com-
bination of selinexor and doxorubicin compared with
single-agent doxorubicin or selinexor in parental 8226
(P ≤ 0.024) and U266 (P ≤ 0.013) MM cell lines and in
drug-resistant 8226B25 (P ≤ 0.015), 8226Dox6 (P ≤ 0.0027),

























Fig. 4 Selinexor inhibits XPO1-TOP2A binding. Parental H929, U266, and 8226 and drug-resistant U266PSR, 8226Dox6, and 8226B25 plateau-density human
MM cells (3 × 106/ml) were treated with selinexor (300 nM), cytospun, and assayed for intracellular co-localization of XPO1 and TOP2A by proximity ligation
assay. A red fluorescent signal was generated only when XPO1 and TOP2A were in close proximity (<40 nm). a Selinexor blocked proximity co-localization
of XPO1 and TOP2A. Inset, selinexor treatment did not affect XPO1 or TOP2A protein levels at 4 h as shown by Western blot. b Analysis of the number of
XPO1-TOP2A foci showed that selinexor significantly decreased the number of foci in the nucleus and whole cells of both parental and drug-resistant
MM cells
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H2AX levels increased four- to sixfold in selinexor- and
doxorubicin-treated cells compared with selinexor or
doxorubicin alone. When cells were transfected with a
TOP2A-specific siRNA, phospho-H2AX levels decreased
significantly (P = 0.0006) (Fig. 6b). Apoptosis was also sig-
nificantly reduced in selinexor- and doxorubicin-treated
cells with TOP2A knockdown (Fig. 6b). These data indi-
cate that DNA damage and subsequent cell death induced
by selinexor/doxorubicin synergy is TOP2A dependent.
Discussion
Drug resistance is the greatest obstacle for treatment of
MM and many other cancers. In this study, we demon-
strated the possibility that acquired drug resistance in
MM may be overcome by a combinatorial therapy in-
cluding the XPO1 inhibitor selinexor with the TOP2
inhibitor doxorubicin. The drug-resistant cell lines used
in this study included human MM made resistant to
doxorubicin (8226Dox6 and 8226Dox40) and cells
made resistant to the proteasome inhibitor bortezomib
(8266B25 and U266PSR); however, all of these cell lines
have a multidrug-resistant phenotype. The mechanism
of drug resistance of 8224Dox6 and 8226Dox40 MM
cell lines has been shown to be due to an upregulation
of the MDR-1 gene [34–36]. These cells have been shown
to be resistant to many chemotherapeutic agents, includ-
ing doxorubicin, daunorubicin, mitoxantrone, acronycine,
etoposide, melphalan, and vincristine. Drug-resistant
8226B25 and U266PSR MM cell lines were developed
by the incremental addition of bortezomib to 8226
and U266 parental cell lines. These cells were found to
be highly resistant to bortezomib, carfilzomib, doxorubi-
cin, and melphalan and therefore also have a multidrug-
resistant phenotype (data not shown). The U266PSR cell
Fig. 5 Comet DNA fragmentation assay. High-density human 8226 and U226 and drug-resistant cell lines 8226Dox6, 8226B25, and U266PSR MM
(2 × 106/mL) were treated with selinexor (100 nM) followed by doxorubicin (5 μM). DNA fragmentation (double-strand breaks) was measured by
the neutral comet assay. Doxorubicin or selinexor, when used as single agents, increased DNA double-strand cleavage compared with untreated
controls. However, selinexor + doxorubicin further increased DNA fragmentation over doxorubicin or selinexor alone
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line expresses a modest increase in Mcl-1 [33] and mark-
edly lower expression of the apoptosis-promoting factor
Bim [31, 32], resulting in enhanced cell survival by inhibit-
ing apoptosis and resulting in multidrug resistance.
The TOP2 poison, doxorubicin, functions by arresting
TOP2A in cleavable complexes, resulting in double-
strand DNA breaks and subsequent apoptotic cell death
of cancer cells [43–45]. Doxorubicin has seen resurgence
in the clinic because of the development of new liposo-
mal formulations [28]. Pegylated liposomal doxorubicin
provides reduced toxicity, increases in vivo circulation
time, and accumulates preferentially in tumors, resulting
in increased efficacy in the treatment of MM [28–30].
We demonstrated by proximity ligation assay that
TOP2A and XPO1 co-localization is disrupted when
MM cells are incubated with selinexor. These data cor-
relate well with previous studies where de novo MM
drug resistance to doxorubicin is caused by nuclear ex-
port of TOP2A, an effect that is reversed by blocking
nuclear export of TOP2A with an XPO1 inhibitor [3, 5,
40, 46]. XPO1 inhibitors such as selinexor prevent ex-
port of TOP2A, keeping it in the nucleus and in close
proximity to the DNA. We found that, when XPO1 in-
hibitors are used with doxorubicin or PLD, DNA dam-
age is increased (comet assay/phospho-H2AX), resulting
in apoptosis and improving the effectiveness of
A
B
Fig. 6 Mechanism for selinexor and doxorubicin synergy. a Parental MM cell lines 8226 and U226 and drug-resistant 8226B25, 8226Dox6, and
U266PSR cells were treated with doxorubicin (2 μM), selinexor (300 nM), or the combination for 20 h. Both parental and drug-resistant cell lines,
when treated with the combination of selinexor and doxorubicin, had significantly increased DNA damage as shown by increased phospho-H2AX
(Ser139) expression (n = 4). b SiRNA knockdown of TOP2A resulted in a substantial decrease in DNA damage (phospho-H2AX (Ser139)) and
apoptosis, suggesting that selinexor and doxorubicin induced DNA damage, and subsequent apoptosis is TOP2A dependent. Inset, TOP2A
knockdown (Western blot)
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doxorubicin. In this study, we demonstrated that this two-
drug combination is also highly effective against drug-
resistant myeloma, in both cell lines and cells derived from
patients. siRNA knockdown of TOP2A significantly de-
creased both DNA damage and apoptosis, confirming this
mechanism of action. The synergistic effect seen with seli-
nexor combined with doxorubicin also translated to drug-
resistant MM cell lines (in vitro and in vivo) and in
MM cells isolated from relapsed/refractory patient
bone marrow. Relapsed/refractory patients received
multiple rounds of chemotherapy that included an
average of 4.7 lines of chemotherapy. These patient
cells, like the drug-resistant cell lines, are also highly
drug-resistant; however, the combination of selinexor
and doxorubicin was effective in the ex vivo treatment
of these cells.
Based on these pre-clinical data, we have initiated a
phase I/II clinical trial with selinexor and PLD in re-
lapsed/refractory multiple myeloma patients. Preliminary
results of the study have been presented at the annual
meeting of the American Society of Clinical Oncology;
and while the dose escalation continues, encouraging
evidence of preliminary efficacy is noted among the 11
response evaluable patients who are heavily pretreated
(median of 6 prior lines of therapy) [47]. Specifically two
patients had a very good partial response, two patients
had a partial response, and another two patients had a
minimal response.
Conclusions
Selinexor, an orally active selective inhibitor of XPO1-
mediated nuclear export, is currently undergoing phase
1 and phase 2 studies in a variety of indications, including
combinations with PLD and carfilzomib, in both relapsed
and refractory MM patients. The results presented in our
study support combinatorial clinical trials in relapsed and
refractory MM, and perhaps other cancers, that utilize
TOP2A therapies.
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